Zymeworks’ HER2 Antibody Hits Target In Pivotal Biliary Tract Cancer Trial
First-In-Class Potential In Disease
Executive Summary
The Canadian firm’s bispecific antibody asset improved response rates in advanced biliary tract cancer patients, potentially setting it up to become the first HER2-targeted drug approved for the disease.
You may also be interested in...
ThirtyFiveBio Makes Its Debut With First-In-Class GPR35 Antagonist Approach
Emerging Company Profile: Backed by $20m in seed funding, the UK firm is going against the grain by antagonizing, instead of agonizing, G protein-coupled receptor 35 with an eye to treating colorectal cancer and other gastrointestinal conditions.
Boehringer To Profit From Jardiance Well Into Second Half Of Decade
The German firm is anticipating a major label expansion in kidney disease for its SGL2 inhibitor later this year, prompting Boehringer to gear up commercial activities as AstraZeneca’s rival Farxiga faces the threat of generic competition.
Path Ahead For Neuraly’s NLY01 Unclear After Phase II Parkinson’s Disappointment
The US firm’s lead program has flunked a mid-stage trial in early Parkinson’s disease and, despite a promising efficacy signal in a younger patient cohort, its future remains uncertain.